腹盆腔恶性肿瘤热灌注化疗与单纯灌注化疗联合高频热疗的临床疗效对比分析  

Comparative analysis of clinical efficacy between intraperitoneal hyperthermic perfusion chemotherapy and intraperitoneal perfusion chemotherapy combined with radiofrequency thermotherapy in the treatment of recurrent or metastatic advanced peritoneo-pelvi

作　　者：陈雍[1] 王根和[1] 张徽声[1] 汪曙红[1] 程鹏[1] CHEN Yong WANG Gen-he ZHANG Hui-sheng WANG Shu-hong CHENG Peng(Department ofoneology, Huangshan City People＇ s Hospital, Anhui Huangshan 245000, Chin)

机构地区：[1]黄山市人民医院肿瘤内科,安徽黄山245000

出　　处：《临床药物治疗杂志》2017年第3期40-45,共6页Clinical Medication Journal

摘　　要：目的:对比分析热灌注化疗与单纯灌注化疗联合高频热疗在治疗复发或转移晚期腹盆腔恶性肿瘤的差异。方法:44例复发转移晚期腹盆腔内肿瘤的患者,治疗组22例,对照组22例。前者通过腹腔热灌注化疗,后者运用单纯灌注化疗联合高频热疗。对疗效、生活质量改善、生存率、腹水控制、不良反应和免疫学改变等指标进行对比分析。结果:治疗组近期有效率为41.2%,而对照组的近期有效率为26.7%(P<0.05)。治疗组平均生存期(17.1±2.3)个月明显高于对照组(14.4±3.4)个月(P<0.05),治疗组严重不良反应(Ⅱ+Ⅳ级)发生率为6.1%,而对照组的发生率为6.5%,没有显著统计学差异(P>0.05)。治疗组腹水控制总有效率(66.7%)高于对照组(31.6%)(P<0.05),而生活质量QOL评分比较,治疗组也明显高于对照组(P<0.05)。治疗组比对照组在提高治疗后CD_4^+/CD_8^+比值,更为明显(P<0.05)。结论:在不增加严重不良反应率的情况下,腹腔热灌注化疗比单纯灌注化疗联用高频热疗在治疗复发或转移晚期盆腹盆腔恶性肿瘤患者,在疗效、生活质量改善、生存率、腹水控制、不良反应和免疫学改变等指标上更具优势。Objective： To compare the difference between intraperitonealhyperthermic perfusion chemotherapy（IHPC）and intraperitoneal perfusion chemotherapy（IPC） combined with radio frequency thermotherapy（RFT） in the treatment of recurrent or metastatic advanced peritoneo-pelvic malignant tumors, and to demonstrate the advantages of IHPC. Methods： 44 cases patients with recurrent or metastatic advanced peritoneo-pelvic malignant tumors were divided into experimental group（22 cases） and control group（22 cases）, respectively. And we analyzed efficacy, quality of life, survival rate, ascites control, SAE（serious adverse event）,immunological changes and other indicators in two groups. Results： The short-term effective rate of experimental group was 41.2%, the mean survival time（17.1 ± 2.3） months in the treatment group was significantly higher than that in the control group（14.4 ± 3.4） months（P〈0.05）, while the recent effective rate of the control group was 26.7%（P〈0.05）. The incidence of SAE in experimental group was 6.1%, while that of the control group was 6.5% without significant difference（P〉0.05）. The total effective rate（66.7%） of ascites control in the experimental group was higher than that in the control group（31.6%）（P〈0.05）.While the quality of life（QOL） score was significantly higher than the control group（P〈0.05）. The ratio of CD4^＋/CD8^＋ in the experimental group improved higher than the control group, more obvious（P〈0.05）. Conclusion： Under the condition of no increase in the rate of serious adverse events, IHPC in the treatment of patients with recurrent or metastatic advanced peritoneo-pelvic malignant tumors have more advantaged than IPC combined with RFT in efficacy, quality of life, improve the survival rate, ascites control, adverse reaction and immunological changes and other indicators.

关 键 词：腹腔热灌注化疗 高频热疗 晚期腹盆腔肿瘤 肿瘤免疫 

分 类 号：R979.1[医药卫生—药品]